Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2beta-Thalassemia 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 6fludarabine 5Specimen Handling 5fludarabine phosphate 4Whole-Body Irradiation 4Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4Biopsy 4venetoclax 3decitabine and cedazuridine drug combination 3Mycophenolic Acid 3Melphalan 3Injections 3Idarubicin 3CPX-351 3Busulfan 3Blood Specimen Collection 3ruxolitinib 2nilotinib 2luspatercept 2ivosidenib 2asciminib 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Liposomes 2Gemtuzumab 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × luspatercept × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡